Establishment Labs (ESTA) Q4 2025: Preserve Drives 2x ASP, U.S. Share Hits 20% in Historic Launch Year
Establishment Labs’ fourth quarter capped a year of rapid U.S. market penetration, propelled by innovation and patient-driven demand for Motiva and Preserve. The company’s minimally invasive platform is expanding the addressable market and lifting average selling prices, while operational leverage is driving margin gains. Management’s guidance and commentary signal confidence in outpacing industry growth and sustaining double-digit expansion through 2027, with upcoming launches and pipeline milestones set to further reshape the breast aesthetics landscape.
Summary
- Minimally Invasive Innovation: Preserve’s premium pricing and new patient draw are accelerating category expansion.
- U.S. Penetration Acceleration: Motiva’s brand-driven adoption is unlocking rapid share gains and deeper account utilization.
- Profitability Pathway: Margin expansion and cash discipline position ESTA for sustainable free cash flow and earnings growth.
Performance Analysis
Establishment Labs delivered a transformative Q4, with revenue up sharply on the back of U.S. Motiva adoption and global demand for minimally invasive offerings. U.S. Motiva sales accounted for $17.3 million in the quarter and $45.6 million for the year, representing roughly 20% of the U.S. augmentation market—a level that took incumbents nearly a decade to reach. The company’s operational leverage was evident as gross margin reached 70.5%, up 200 basis points year over year, and adjusted EBITDA swung to a $5.5 million profit from a prior $13.1 million loss. Net operating loss narrowed by 79%, reflecting disciplined cost management even as commercial investments scaled.
Across geographies, EMEA contributed 41% of Q4 sales, the U.S. 27%, Latin America 18%, and Asia Pacific 14%. Direct markets in Europe posted over 20% growth for the third straight quarter, while Latin America stabilized and APAC showed improved distributor performance. Preserve, the company’s minimally invasive breast augmentation platform, delivered global revenue above expectations and is now available in 33 markets. Notably, Preserve procedures command more than twice the ASP of traditional augmentation and are attracting new patients previously uninterested in surgery, underpinning both volume and revenue tailwinds.
- U.S. Motiva Share Surge: Achieved 20% U.S. augmentation market share in year one, a milestone that signals product-market fit and brand pull.
- Margin Expansion: 330 basis point full-year gross margin improvement reflects geographic and product mix shift toward higher-value U.S. and minimally invasive procedures.
- Cash Discipline: Q4 cash increased to $75.6 million, with no further capital needs anticipated as operational leverage improves.
Momentum into 2026 is strong, with January and February outpacing expectations and ongoing salesforce expansion targeting deeper account penetration. Management expects U.S. revenue to exceed 30% of sales in 2026, with Preserve and new pipeline launches set to drive further upside.
Executive Commentary
"The $45.6 million in U.S. revenue and approximate 20% augmentation market share exiting 2025 is something that took the last new entrant almost 10 years to achieve, and we did it in one."
Peter Caldini, Chief Executive Officer
"We expect our OUS business will grow in the single digits and the U.S. will exceed 30% of overall sales, which is up from approximately 22% in 2025. Gross margins are expected to increase 200 to 300 basis points."
Raj Dinhoy, Chief Financial Officer
Strategic Positioning
1. U.S. Market Disruption and Brand-Led Demand
Motiva’s rapid adoption in the U.S. underscores pent-up demand for differentiated breast aesthetics. Patient-driven requests and surgeon advocacy are fueling account onboarding, with over 1,500 practices signed in 15 months and high conversion rates at premium pricing. Management sees significant room to deepen penetration within existing accounts, as many remain early in their Motiva ramp.
2. Preserve: Expanding the Category and ASPs
Preserve, the minimally invasive augmentation platform, is catalyzing market expansion by attracting patients previously unwilling to consider surgery. With ASPs over twice that of traditional procedures and surgeons charging 30–50% premiums, Preserve is both a volume and margin driver. Management expects at least 200 trained surgeons by year-end and sees Preserve as a potential 50% share of U.S. revenues over time.
3. Global Diversification and Direct Market Focus
International operations remain resilient, with Europe’s direct markets consistently posting 20%+ growth and Latin America stabilizing. The APAC region, particularly China, is showing early signs of improvement after a slow start, reflecting management’s intensified distributor engagement and market development efforts.
4. R&D Pipeline and Portfolio Expansion
Ongoing investment in innovation is a core differentiator. The upcoming launches of smaller Motiva sizes, the reconstructive indication (which could double the U.S. addressable market), and next-gen products like Ergonomics2 and MIA are expected to sustain growth and further distance ESTA from legacy competitors.
5. Operational Leverage and Leadership Transition
Cost discipline and scalability are translating revenue growth to the bottom line. SG&A remained flat year over year despite commercial expansion, and the company expects incremental operating spend to remain well below top-line growth rates. Leadership transitions, including a new CFO and a dedicated SVP of Global Strategy, are designed to sustain execution and unlock further value from the innovation pipeline.
Key Considerations
The quarter marks a structural inflection in ESTA’s business model, with innovation and direct sales execution driving both share gains and margin expansion. Investors should weigh the following:
Key Considerations:
- Preserve’s Market-Creating Effect: Early data show 15% of Preserve patients were new to augmentation, supporting management’s thesis of category expansion.
- Salesforce Productivity Ramp: Up to 15 new U.S. reps (many already hired) are expected to accelerate both account acquisition and share-of-wallet penetration.
- Reconstruction Approval Upside: FDA submission for Motiva in reconstruction, if approved, could double the U.S. TAM and further lift ASPs and margins.
- Cash Flow Inflection: Guidance for first positive cash flow quarter in 2026 and full-year profitability in 2027 removes equity overhang and supports reinvestment.
Risks
Key risks center on FDA approval timing, especially for the reconstructive indication and pipeline launches, as well as the pace of U.S. account penetration and surgeon adoption. International distributor variability, macroeconomic sensitivity in elective procedures, and execution on China’s ramp remain watchpoints. Any delay or underperformance in these areas could impact the growth and margin trajectory outlined by management.
Forward Outlook
For Q1 2026, Establishment Labs guided to:
- Sequential U.S. revenue growth, despite typical seasonality headwinds in the broader market.
- Continued global demand for minimally invasive procedures, with Preserve expected to exceed $30 million in sales for the year.
For full-year 2026, management raised guidance to:
- $264–266 million in revenue, representing 25%+ growth.
- Gross margin expansion of 200–300 basis points.
- Adjusted EBITDA positive in every quarter and free cash flow positive in the second half.
Management highlighted several factors that will drive upside:
- Ongoing U.S. share gains and deeper account utilization for Motiva and Preserve.
- Global direct market growth and incremental launches (small sizes, reconstruction, pipeline).
Takeaways
Establishment Labs is executing a rare dual play of market expansion and premiumization, with innovation and brand momentum translating to rapid share gains and margin leverage.
- U.S. Launch Outperformance: Motiva’s 20% share in its first full year is a historic achievement, validating the company’s differentiated value proposition and commercial strategy.
- Preserve’s Disruptive Impact: The minimally invasive platform is both expanding the patient pool and driving 2x ASP, setting up a multi-year margin and revenue tailwind.
- Global Growth and Profitability Path: With positive EBITDA, rising gross margins, and cash flow visibility, ESTA is positioned to sustain double-digit growth and reinvest for further innovation.
Conclusion
ESTA’s Q4 and full-year results demonstrate a business pivoting from innovation to operational leverage at scale, with U.S. momentum, Preserve’s market-creating effect, and a robust global footprint supporting management’s bullish multi-year outlook. Investors should monitor execution on pipeline launches and account penetration as key drivers of sustained outperformance.
Industry Read-Through
Establishment Labs’ rapid U.S. share capture and success with minimally invasive, premium-priced procedures signal a paradigm shift in the breast aesthetics industry. Legacy competitors face mounting pressure to innovate or risk share loss, as patient-driven demand and transparency reshape the category. ESTA’s ability to expand the addressable market, not just take share, has implications for all players in elective surgery and medical aesthetics, highlighting the power of differentiated R&D and direct commercial execution. The company’s global diversification and leverage of social media-driven patient education offer a blueprint for medtech disruptors targeting entrenched markets.